Robert Abraham, Ph.D.
Senior Vice President, Group Head of Oncology Research and Development, Pfizer
Robert (Bob) Abraham is Senior Vice President and Group Head, Oncology R&D Group in Pfizer Worldwide Research and Development (WRD). He serves as a standing member of the WRD leadership team, and founded and directed the Pfizer WRD Postdoc Training Program. Prior to these roles, Bob served in Wyeth Research as Vice President of Oncology Research, one of the five therapeutic areas in Wyeth Discovery Research.
Prior to joining Wyeth, Bob was a Professor at the Sanford-Burnham Institute for Medical Research (SBIMR) in La Jolla, CA. He was the founding Director of the Signal Transduction Research Program and served as the Director of the SBIMR Cancer Research Center, successfully guiding the center to a renewal of its designation as one of nine National Cancer Institute-sponsored basic science centers in the United States. Bob retains an appointment as an Adjunct Professor at the SBIMR, together with an Adjunct Professor Appointment in Pharmacology at the University of California – San Diego. From 1998-2001, Bob was a Professor in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center and was the first recipient of the Glaxo-Wellcome Chair of Molecular Cancer Biology at Duke. He also served as Associate Director of Translational Research in the Duke Comprehensive Cancer Center. Before his arrival at Duke University, Bob was at the Mayo Clinic in Rochester, MN, where he rose through the ranks to become a Professor in both the Department of Immunology and Department of Pharmacology. From 1997-1998, he also served as Director of Basic Sciences in the Mayo Comprehensive Cancer Center. Bob’s major research interests included characterization and functional analysis of the mammalian Target of Rapamycin signaling pathway, cancer metabolism, signal transduction mechanisms in T-lymphocytes, and molecular mechanisms underlying cellular responses to DNA damage. He also holds several patents related to anticancer drug development.
Bob received his B.S. in Biology from Bucknell University, Lewisburg, PA in 1974 and subsequently completed his Ph.D. studies in Pharmacology at the University of Pittsburgh, Pittsburgh, PA. In 1981, Bob was a Postdoctoral Fellow in Pharmacology and Immunology at the Mayo Clinic. Bob is the author of over 210 scientific publications and has served on and chaired grant review panels at the National Institutes of Health. He is a reviewer for many top journals, including Nature, Science, and Cell. He has received several awards for his scientific contributions, including the Legacy Laureate Award as an outstanding alumnus of the University of Pittsburgh.